GlaxoSmithKline plc  

(Public, LON:GSK)   Watch this stock  
Find more results for GSK
1,468.49
-10.01 (-0.68%)
Nov 27 - Close
LON real-time data - Disclaimer
Currency in GBX unless noted
Range     -
52 week 1,200.67 - 1,709.00
Open     -
Vol / Avg. 0.00/9.08M
Mkt cap 71.87B*
P/E 17.11
Div/yield 19.00/5.45*
EPS 0.86*
Shares 4.86B
Beta     -
Inst. own     -
*GBP
Feb 4, 2015
Q4 2014 GlaxoSmithKline PLC Earnings Release - 8:00AM GMT - Add to calendar
Dec 18, 2014
GlaxoSmithKline PLC Ordinary Shareholders Meeting - 10:30AM GMT - Add to calendar
Dec 3, 2014
GlaxoSmithKline PLC at Berenberg European Conference Add to calendar
Oct 22, 2014
Q3 2014 GlaxoSmithKline PLC Earnings Call
Oct 22, 2014
Q3 2014 GlaxoSmithKline PLC Earnings Release
Sep 19, 2014
GlaxoSmithKline PLC at Bank of America Merrill Lynch Global Healthcare Conference
Sep 9, 2014
GlaxoSmithKline PLC Investor and Analyst Event at the European Respiratory Society 2014
  

Key stats and ratios

Q3 (Sep '14) 2013
Net profit margin 6.82% 21.23%
Operating margin 12.45% 27.58%
EBITD margin - 31.21%
Return on average assets 3.90% 13.47%
Return on average equity 28.82% 84.96%
Employees 99,817 -
CDP Score - 98 A

Address

980 Great West Road
BRENTFORD, ENG TW8 9GS
United Kingdom - Map
+44-20-80475000 (Phone)
+44-20-80477807 (Fax)

Website links

External links

Analyst Estimates - BusinessWeek
Options - MarketWatch
Director Dealings - Yahoo Finance

Description

GlaxoSmithKline plc (GSK) is global healthcare group, which is engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products, including vaccines, over-the-counter (OTC) medicines and health-related consumer products. GSK�s principal pharmaceutical products include medicines in therapeutic areas: respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, antibacterials, oncology and emesis, dermatology, rare diseases, immuno-inflammation, vaccines and human immunodeficiency virus (HIV). The Company operates in three primary areas of business: Pharmaceuticals, Vaccines and Consumer Healthcare. On January 30, 2013, GSK acquired additional 29.3% interest in GlaxoSmithKline Consumer Healthcare Ltd. In May 2013, GlaxoSmithKline PLC acquired Okairos AG. In December 2013, Suntory Beverage & Food Ltd fully acquired Lucozade Ribena Suntory Limited from GlaxoSmithKline plc.

Officers and directors

Andrew Philip Witty Chief Executive Officer, Executive Director
Age: 49
Simon Dingemans Chief Financial Officer, Executive Director
Age: 50
Moncef Slaoui Chairman, Executive Director
Age: 54
Deirdre P. Connelly President - North American Pharmaceuticals
Age: 53
Roger Connor President - Global Manufacturing & Supply
Shah Abbas Hussain President - Europe, Japan & EMAP
Age: 47
Patrick Vallance President - Pharmaceuticals R&D
Emma Walmsley President - Consumer Healthcare Worldwide
Daniel Troy Senior Vice President, General Counsel
Claire Thomas Senior Vice President - Human Resources